References
1. FIND. COVID-19 pipeline. 2021.
https://www.finddx.org/covid-19/pipeline/ (Accessed March 2021).
2. The European Centre For Disease Prevention and Control. COVID-19
Testing strategies and objectives. 2020.
https://www.ecdc.europa.eu/en/covid-19/surveillance/testing-strategies
(Accessed March 2021).
3. The World Health Organization. Diagnostic testing for SARS-CoV-2.
2020.
https://www.who.int/publications/i/item/diagnostic-testing-for-sars-cov-2
(Accessed March 2021).
4. Arevalo-Rodriguez I, Seron P, Buitrago-Garcia D, et al.
Recommendations for SARS-CoV-2/COVID-19 testing: a scoping review of
current guidance. BMJ Open 2021; 11 (1): e043004.
5. The US Centers for Disease Prevention and Control. Testing for
COVID-19. 2020.
https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/testing.html
(Accessed March 2021).
6. Mostafa HH, Hardick J, Morehead E, Miller JA, Gaydos CA, Manabe YC.
Comparison of the analytical sensitivity of seven commonly used
commercial SARS-CoV-2 automated molecular assays. J Clin Virol2020; 130 : 104578.
7. Yu CY, Chan KG, Yean CY, Ang GY. Nucleic Acid-Based Diagnostic Tests
for the Detection SARS-CoV-2: An Update. Diagnostics (Basel)2021; 11 (1).
8. The US Food and Drug Administration. SARS-CoV-2 Reference Panel
Comparative Data. 2020.
https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/sars-cov-2-reference-panel-comparative-data
(Accessed February 2021).
9. Hologic. Hologic SARS-CoV-2 Assays. 2021.
https://www.hologic.com/hologic-products/diagnostic-solutions/hologic-sars-cov-2-assays
(Accessed March 2021).
10. Rodel J, Egerer R, Suleyman A, et al. Use of the variplex SARS-CoV-2
RT-LAMP as a rapid molecular assay to complement RT-PCR for COVID-19
diagnosis. J Clin Virol 2020; 132 : 104616.
11. Roche Diagnostics. Elecsys SARS-CoV-2 Antigen. 2021.
https://diagnostics.roche.com/global/en/products/params/elecsys-sars-cov-2-antigen-test.html
(Accessed March 2021).
12. Hayer J, Kasapic D, Zemmrich C. Real-world clinical performance of
commercial SARS-CoV-2 rapid antigen tests in suspected COVID-19: A
systematic meta-analysis of available data as per November 20, 2020.medRxiv 2020: 2020.12.22.20248614.
13. The US Food and Drug Administration. EUA Authorized Serology Test
Performance. 2021.
https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance.
(Accessed March 2021)
14. The World Health Organization. COVID-19 Target product profiles for
priority diagnostics to support response to the COVID-19 pandemic v.1.0.
2020.
https://www.who.int/publications/m/item/covid-19-target-product-profiles-for-priority-diagnostics-to-support-response-to-the-covid-19-pandemic-v.0.1
(Accessed March 2021).
15. Wirden M, Feghoul L, Bertine M, et al. Multicenter comparison of the
Cobas 6800 system with the RealStar RT-PCR kit for the detection of
SARS-CoV-2. J Clin Virol 2020; 130 : 104573.
16. Gorzalski AJ, Tian H, Laverdure C, et al. High-Throughput
Transcription-mediated amplification on the Hologic Panther is a highly
sensitive method of detection for SARS-CoV-2. J Clin Virol 2020;129 : 104501.
17. Fowler VL, Armson B, Gonzales JL, et al. A highly effective
reverse-transcription loop-mediated isothermal amplification (RT-LAMP)
assay for the rapid detection of SARS-CoV-2 infection. J Infect2021; 82 (1): 117-25.
18. Mautner L, Baillie CK, Herold HM, et al. Rapid point-of-care
detection of SARS-CoV-2 using reverse transcription loop-mediated
isothermal amplification (RT-LAMP). Virol J 2020; 17 (1):
160.
19. Osterdahl MF, Lee KA, Lochlainn MN, et al. Detecting SARS-CoV-2 at
point of care: preliminary data comparing loop-mediated isothermal
amplification (LAMP) to polymerase chain reaction (PCR). BMC
Infect Dis 2020; 20 (1): 783.
20. Freire-Paspuel B, Garcia-Bereguiain MA. Low clinical performance of
the Isopollo COVID-19 detection kit (M Monitor, South Korea) for RT-LAMP
SARS-CoV-2 diagnosis: A call for action against low quality products for
developing countries. Int J Infect Dis 2021; 104 : 303-5.
21. Iacobucci G. Covid-19: Mass population testing is rolled out in
Liverpool. BMJ 2020; 371 : m4268.
22. Iacobucci G. Covid-19: Rapid test missed over 50% of positive cases
in Manchester pilot. BMJ 2020; 371 : m4323.
23. The UK Department of Health and Social Care. Clinical evaluation
confirms accuracy of LAMP test. Gov.uk; 2020.
24. Lanser L, Bellmann-Weiler R, Ottl KW, et al. Evaluating the clinical
utility and sensitivity of SARS-CoV-2 antigen testing in relation to
RT-PCR Ct values. Infection 2020.
25. Mattiuzzi C, Henry BM, Lippi G. Making sense of rapid antigen
testing in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
diagnostics. Diagnosis (Berl) 2020.
26. Dinnes J, Deeks JJ, Adriano A, et al. Rapid, point-of-care antigen
and molecular-based tests for diagnosis of SARS-CoV-2 infection.Cochrane Database Syst Rev 2020; 8 : CD013705.
27. Lindner AK, Nikolai O, Kausch F, et al. Head-to-head comparison of
SARS-CoV-2 antigen-detecting rapid test with self-collected nasal swab
versus professional-collected nasopharyngeal swab. Eur Respir J2021.
28. Houston H, Gupta-Wright A, Toke-Bjolgerud E, Biggin-Lamming J, John
L. Diagnostic accuracy and utility of SARS-CoV-2 antigen lateral flow
assays in medical admissions with possible COVID-19. J Hosp
Infect 2021.
29. Chen M, Qin R, Jiang M, Yang Z, Wen W, Li J. Clinical applications
of detecting IgG, IgM or IgA antibody for the diagnosis of COVID-19: A
meta-analysis and systematic review. Int J Infect Dis 2021;104 : 415-22.
30. Pisanic N, Randad PR, Kruczynski K, et al. COVID-19 Serology at
Population Scale: SARS-CoV-2-Specific Antibody Responses in Saliva.J Clin Microbiol 2020; 59 (1).
31. Long QX, Liu BZ, Deng HJ, et al. Antibody responses to SARS-CoV-2 in
patients with COVID-19. Nat Med 2020; 26 (6): 845-8.
32. Röltgen K, Powell AE, Wirz OF, et al. Defining the features and
duration of antibody responses to SARS-CoV-2 infection associated with
disease severity and outcome. Science Immunology 2020;5 (54): eabe0240.
33. Schaffner A, Risch L, Weber M, et al. Sustained SARS-CoV-2
nucleocapsid antibody levels in nonsevere COVID-19: a population-based
study. Clin Chem Lab Med 2020; 59 (2): e49-e51.
34. Fujita K, Kada S, Kanai O, et al. Quantitative SARS-CoV-2 Antibody
Screening of Healthcare Workers in the Southern Part of Kyoto City
During the COVID-19 Pre-pandemic Period. Front Public Health2020; 8 : 595348.
35. Mahase E. Covid-19: Antibody prevalence in England fell from 6.0%
to 4.4% over three months, study finds. BMJ 2020; 371 :
m4163.
36. Vogl T, Leviatan S, Segal E. SARS-CoV-2 antibody testing for
estimating COVID-19 prevalence in the population. Cell Rep Med2021: 100191.
37. Bradley T, Grundberg E, Selvarangan R. Antibody responses boosted in
seropositive healthcare workers after single dose of SARS-CoV-2 mRNA
vaccine. medRxiv 2021.
38. Mallett S, Allen AJ, Graziadio S, et al. At what times during
infection is SARS-CoV-2 detectable and no longer detectable using
RT-PCR-based tests? A systematic review of individual participant data.BMC Medicine 2020; 18 (1): 346.
39. Sethuraman N, Jeremiah SS, Ryo A. Interpreting Diagnostic Tests for
SARS-CoV-2. JAMA 2020; 323 (22): 2249-51.
40. Boger B, Fachi MM, Vilhena RO, Cobre AF, Tonin FS, Pontarolo R.
Systematic review with meta-analysis of the accuracy of diagnostic tests
for COVID-19. Am J Infect Control 2021; 49 (1): 21-9.
41. Gonzalez-Gonzalez E, Lara-Mayorga IM, Rodriguez-Sanchez IP, et al.
Colorimetric loop-mediated isothermal amplification (LAMP) for
cost-effective and quantitative detection of SARS-CoV-2: the change in
color in LAMP-based assays quantitatively correlates with viral copy
number. Anal Methods 2021; 13 (2): 169-78.
42. Huang WE, Lim B, Hsu CC, et al. RT-LAMP for rapid diagnosis of
coronavirus SARS-CoV-2. Microb Biotechnol 2020; 13 (4):
950-61.
43. Nagura-Ikeda M, Imai K, Tabata S, et al. Clinical Evaluation of
Self-Collected Saliva by Quantitative Reverse Transcription-PCR
(RT-qPCR), Direct RT-qPCR, Reverse Transcription-Loop-Mediated
Isothermal Amplification, and a Rapid Antigen Test To Diagnose COVID-19.J Clin Microbiol 2020; 58 (9).
44. The US Centers for Disease Prevention and Control. COVID-19 Pooling
Procedures. 2020.
https://www.cdc.gov/coronavirus/2019-ncov/lab/pooling-procedures.html
(Accessed March 2021).
45. Viracor. Emergency Use Authorisation (EUA) Summary Viracor
SARS-CoV-2 Assay. 2021. https://www.fda.gov/media/143069/download
(Accessed March 2021 2021).
46. Perkin Elmer. Instructions for PerkinElmer® New Coronavirus Nucleic
Acid Detection Kit 2020. https://www.fda.gov/media/136410/download
(Accessed March 2021).
47. Public Health England. Standard operating procedure: Pooling of
asymptomatic SARS-CoV-2 COVID-19 sample for (PCR/or other) testing.
2020.
https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2020/09/C0777-sample-pooling-sop-v1.pdf
(Accessed February 2021).
48. Petrovan V, Vrajmasu V, Bucur AC, et al. Evaluation of Commercial
qPCR Kits for Detection of SARS-CoV-2 in Pooled Samples.Diagnostics (Basel) 2020; 10 (7).
49. Torres I, Albert E, Navarro D. Pooling of nasopharyngeal swab
specimens for SARS-CoV-2 detection by RT-PCR. J Med Virol 2020;92 (11): 2306-7.
50. Guglielmi G. Fast corornavirus tests: what they can and can’t do.
Nature. 2020.
51. The US Food and Drug Administration. Coronavirus Disease 2019
Testing Basics. 2019.
https://www.fda.gov/consumers/consumer-updates/coronavirus-disease-2019-testing-basics
(Accessed February 2021).
52. The European Centre for Disease Control. Options fo the use of rapid
antigen tests for COVID-19 in the EU/EEA and the UK. 2020.
https://www.ecdc.europa.eu/sites/default/files/documents/Options-use-of-rapid-antigen-tests-for-COVID-19.pdf
(Accessed February 2021).
53. The US Centers for Disease Prevention and Control. Using Antigen
Tests. 2020.
https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antigen-tests-guidelines.html
(Accessed February 2021).
54. B-Fast Network of the National Research Network for COVID-19;
Protzer UK, I; Renz, H; Busch, D; Denkinger, C; Fatkenheuer, G; Klein,
F; Krausslich, H-G; Krefing, D; Schiethauer, S. Position paper of the
B-FAST network in the National Research Network of University Medicine
on COVID-19 on the application and approval practice of rapid antigen
tests for the detection of the new coronavirus, SARS-CoV-2. 2021.
55. Carpenter CR. Rapid antigen and molecular tests had varied
sensitivity and >/=97% specificity for detecting
SARS-CoV-2 infection. Ann Intern Med 2020; 173 (12):
JC69.
56. Mak GC, Cheng PK, Lau SS, et al. Evaluation of rapid antigen test
for detection of SARS-CoV-2 virus. J Clin Virol 2020;129 : 104500.
57. Chan CP, Wong NS, Leung CC, Lee SS. Positive impact of measures
against COVID-19 on reducing influenza in the Northern Hemisphere.J Travel Med 2020; 27 (8).
58. Chow A, Hein AA, Kyaw WM. Unintended Consequence: Influenza plunges
with public health response to COVID-19 in Singapore. J Infect2020; 81 (2): e68-e9.
59. Kuo SC, Shih SM, Chien LH, Hsiung CA. Collateral Benefit of COVID-19
Control Measures on Influenza Activity, Taiwan. Emerg Infect Dis2020; 26 (8): 1928-30.
60. Noh JY, Seong H, Yoon JG, Song JY, Cheong HJ, Kim WJ. Social
Distancing against COVID-19: Implication for the Control of Influenza.J Korean Med Sci 2020; 35 (19): e182.
61. Olsen SJ, Azziz-Baumgartner E, Budd AP, et al. Decreased Influenza
Activity During the COVID-19 Pandemic - United States, Australia, Chile,
and South Africa, 2020. MMWR Morb Mortal Wkly Rep 2020;69 (37): 1305-9.
62. Islam MN, Dipi RM, Mostafa SN, Datta A. Progression of Disease in
COVID-19 Patients Evaluated by Chest CT Imgaing and Correlated with
Clinical Parameters. Mymensingh Med J 2021; 30 (1):
182-8.
63. Waller JV, Kaur P, Tucker A, et al. Diagnostic Tools for Coronavirus
Disease (COVID-19): Comparing CT and RT-PCR Viral Nucleic Acid Testing.AJR Am J Roentgenol 2020; 215 (4): 834-8.
64. Tofighi S, Najafi S, Johnston SK, Gholamrezanezhad A. Low-dose CT in
COVID-19 outbreak: radiation safety, image wisely, and image gently
pledge. Emerg Radiol 2020; 27 (6): 601-5.
65. The World Health Organization. COVID-19 Clinical management. 2021.
https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1
(Accessed March 2021).
66. Mockel M, Corman VM, Stegemann MS, et al. SARS-CoV-2 Antigen Rapid
Immunoassay for Diagnosis of COVID-19 in the Emergency Department.Biomarkers 2021: 1-13.
67. Wake RM, Morgan M, Choi J, Winn S. Reducing nosocomial transmission
of COVID-19: implementation of a COVID-19 triage system. Clin Med
(Lond) 2020; 20 (5): e141-e5.
68. The US Food and Drug Administration. COVID-19 Test Uses: FAQs on
Testing for SARS-CoV-2. 2021.
https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/covid-19-test-uses-faqs-testing-sars-cov-2
(accessed March 2021 2021).
69. Huang J, Zheng L, Li Z, et al. Kinetics of SARS-CoV-2 positivity of
infected and recovered patients from a single center. Scientific
Reports 2020; 10 (1): 18629.
70. Kim SM, Hwang YJ, Kwak Y. Prolonged SARS-CoV-2 detection and
reversed RT-PCR results in mild or asymptomatic patients. Infect
Dis (Lond) 2021; 53 (1): 31-7.
71. Landi F, Gremese E, Rota E, et al. Positive RT-PCR nasopharyngeal
swab in patients recovered from COVID-19 disease: When does quarantine
really end? The Journal of infection 2020; 81 (6): e1-e3.
72. Pray IW, Ford L, Cole D, et al. Performance of an Antigen-Based Test
for Asymptomatic and Symptomatic SARS-CoV-2 Testing at Two University
Campuses - Wisconsin, September-October 2020. MMWR Morb Mortal
Wkly Rep 2021; 69 (5152): 1642-7.
73. Carpenter CR, Mudd PA, West CP, Wilber E, Wilber ST. Diagnosing
COVID-19 in the Emergency Department: A Scoping Review of Clinical
Examinations, Laboratory Tests, Imaging Accuracy, and Biases.Academic emergency medicine : official journal of the Society for
Academic Emergency Medicine 2020; 27 (8): 653-70.
74. The European Centre for Disease Prevention and Control. Novel
coronavirus (SARS-CoV-2): Discharge criteria for confirmed COVID-19
cases – When is it safe to discharge COVID-19 cases from the hospital
or end home isolation? . 2020.
https://www.ecdc.europa.eu/sites/default/files/documents/COVID-19-Discharge-criteria.pdf
(accessed February 2021 2021).
75. The US Centers for Disease Prevention and Control. Discontinuation
of Transmission-Based Precautions and Disposition of Patients with
SARS-CoV-2 Infection in Healthcare Settings. 2021.
https://www.cdc.gov/coronavirus/2019-ncov/hcp/disposition-hospitalized-patients.html
(Accessed March 2021).
76. Robert Koch Institut. COVID-19 : Release Criteria from Isolation.
2021.
https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Entlassmanagement.html;jsessionid=5BED1087E0E0E4BCC211959326363099.internet061?nn=13490888
(Accessed March 2021).
77. Elsayed SM, Reddy MK, Murthy PM, et al. The Possibility and Cause of
Relapse After Previously Recovering From COVID-19: A Systematic Review.Cureus 2020; 12 (9): e10264-e.
78. Nakajima Y, Ogai A, Furukawa K, et al. Prolonged viral shedding of
SARS-CoV-2 in an immunocompromised patient. Journal of Infection
and Chemotherapy 2021; 27 (2): 387-9.
79. Rao SN, Manissero D, Steele VR, Pareja J. A Systematic Review of the
Clinical Utility of Cycle Threshold Values in the Context of COVID-19.Infect Dis Ther 2020; 9 (3): 573-86.
80. Piralla A, Ricchi M, Cusi MG, et al. Residual SARS-CoV-2 RNA in
nasal swabs of convalescent COVID-19 patients: Is prolonged quarantine
always justified? International Journal of Infectious Diseases2021; 102 : 299-302.
81. Bielecki M, Patel D, Hinkelbein J, et al. Air travel and COVID-19
prevention in the pandemic and peri-pandemic period: A narrative review.Travel Med Infect Dis 2021; 39 : 101915.
82. Lohse S, Pfuhl T, Berko-Gottel B, et al. Pooling of samples for
testing for SARS-CoV-2 in asymptomatic people. Lancet Infect Dis2020; 20 (11): 1231-2.
83. Frnda J, Durica M. On Pilot Massive COVID-19 Testing by Antigen
Tests in Europe. Case Study: Slovakia. Infect Dis Rep 2021;13 (1): 45-57.
84. Scohy A, Anantharajah A, Bodeus M, Kabamba-Mukadi B, Verroken A,
Rodriguez-Villalobos H. Low performance of rapid antigen detection test
as frontline testing for COVID-19 diagnosis. J Clin Virol 2020;129 : 104455.
85. Control ECfDPa. Infection prevention and control and preparedness
for COVID-19 in healthcare settings. 2020 (accessed February 2021 2021).
86. Gholami M, Fawad I, Shadan S, et al. COVID-19 and healthcare
workers: A systematic review and meta-analysis. International
Journal of Infectious Diseases 2021; 104 : 335-46.
87. DiFiori JP, Green G, Meeuwisse W, Putukian M, Solomon GS, Sills A.
Return to sport for North American professional sport leagues in the
context of COVID-19. British Journal of Sports Medicine 2020:
bjsports-2020-103227.
88. Mooney M, Perera NKP, Broderick C, et al. A deep dive into testing
and management of COVID-19 for Australian high performance and
professional sport. J Sci Med Sport 2020; 23 (7): 664-9.
89. Pedersen L, Lindberg J, Lind RR, Rasmusen H. Reopening elite sport
during the COVID-19 pandemic: Experiences from a controlled return to
elite football in Denmark. Scand J Med Sci Sports 2021.
90. Viner RM, Mytton OT, Bonell C, et al. Susceptibility to SARS-CoV-2
Infection Among Children and Adolescents Compared With Adults: A
Systematic Review and Meta-analysis. JAMA Pediatrics 2021;175 (2): 143-56.
91. Otte im Kampe E, Lehfeld A-S, Buda S, Buchholz U, Haas W.
Surveillance of COVID-19 school outbreaks, Germany, March to August
2020. Eurosurveillance 2020; 25 (38): 2001645.
92. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the
ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim
analysis of four randomised controlled trials in Brazil, South Africa,
and the UK. The Lancet 2021; 397 (10269): 99-111.
93. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the
BNT162b2 mRNA Covid-19 Vaccine. New England Journal of Medicine2020; 383 (27): 2603-15.
94. The New York Times. Coronavirus Vaccine Tracker. 2021.
https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html
(Accessed March 2021).
95. Hodgson SH, Mansatta K, Mallett G, Harris V, Emary KRW, Pollard AJ.
What defines an efficacious COVID-19 vaccine? A review of the challenges
assessing the clinical efficacy of vaccines against SARS-CoV-2.The Lancet Infectious Diseases 2021; 21 (2): e26-e35.
96. The World Health Organization. Guidelines on clinical evaluation of
vaccine: regulatory expectations. 2016.
https://www.who.int/biologicals/expert_committee/Clinical_changes_IK_final.pdf
(Accessed February 2021).
97. Manisty C, Otter AD, Treibel TA, et al. Antibody response to first
BNT162b2 dose in previously SARS-CoV-2-infected individuals.Lancet 2021.
98. Muller L, Ostermann PN, Walker A, et al. Sensitivity of
anti-SARS-CoV-2 serological assays in a high-prevalence setting.Eur J Clin Microbiol Infect Dis 2021.
99. Kohmer N, Westhaus S, Ruhl C, Ciesek S, Rabenau HF. Brief clinical
evaluation of six high-throughput SARS-CoV-2 IgG antibody assays.J Clin Virol 2020; 129 : 104480.
100. Ozcurumez MK, Ambrosch A, Frey O, et al. SARS-CoV-2 antibody
testing-questions to be asked. J Allergy Clin Immunol 2020;146 (1): 35-43.
101. The US Centers for Disease Prevention and Control. Genomic
surveillance for SARS-CoV-2. 2021.
https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance.html
(Accessed February 2021).
102. Wu K, Werner AP, Moliva JI, et al. mRNA-1273 vaccine induces
neutralizing antibodies against spike mutants from global SARS-CoV-2
variants. bioRxiv 2021: 2021.01.25.427948.
103. US Food and Drug Administration. Genetic Variants of SARS-CoV-2 May
Lead to False Negative Results with Molecular Tests for Detection of
SARS-CoV-2 - Letter to Clinical Laboratory Staff and Health Care
Providers. 2021.
https://www.fda.gov/medical-devices/letters-health-care-providers/genetic-variants-sars-cov-2-may-lead-false-negative-results-molecular-tests-detection-sars-cov-2
(Accessed February 2021).
104. Buchta C, Görzer I, Chiba P, et al. Variability of cycle threshold
values in an external quality assessment scheme for detection of the
SARS-CoV-2 virus genome by RT-PCR. Clinical Chemistry and
Laboratory Medicine (CCLM) 2020.
105. Javalkote VS, Kancharla N, Bhadra B, et al. CRISPR-based assays for
rapid detection of SARS-CoV-2. Methods 2020.
106. Xiong E, Jiang L, Tian T, et al. Simultaneous Dual-Gene Diagnosis
of SARS-CoV-2 Based on CRISPR/Cas9-Mediated Lateral Flow Assay.Angew Chem Int Ed Engl 2020.